Valuation: ADC Therapeutics SA

Market Cap 190M 172M 159M 144M 271M 17.74B 282M 1.92B 759M 9.57B 712M 697M 30.25B P/E 2026 *
-1.94x
P/E 2027 * -2.1x
Enterprise Value 190M 172M 159M 144M 271M 17.74B 282M 1.92B 759M 9.57B 712M 697M 30.25B EV / Sales 2026 *
2.18x
EV / Sales 2027 * 1.87x
Free-Float
85.18%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: ADC Therapeutics SA

1 day+8.00%
1 week-10.60%
Current month-11.76%
1 month-3.57%
3 months+22.73%
6 months-58.46%
Current year-61.76%
1 week 1.24
Extreme 1.24
1.58
1 month 1.24
Extreme 1.24
1.86
Current year 0.78
Extreme 0.7796
4.98
1 year 0.78
Extreme 0.7796
4.98
3 years 0.68
Extreme 0.684
6.04
5 years 0.36
Extreme 0.359908
24.82
10 years 0.36
Extreme 0.359908
56.59
Manager TitleAgeSince
Chief Executive Officer 53 2022-05-08
Director of Finance/CFO 54 2022-12-18
Chief Tech/Sci/R&D Officer 52 2024-09-30
Director TitleAgeSince
Director/Board Member 59 2025-05-31
Director/Board Member 67 2019-05-31
Chairman 59 2020-02-29
Date Insider Type Main position Quantity % Market Cap. Importance
6/30/26 Free

Chief Executive Officer

675,000 0.5307%
6/30/26 Free

Chief Financial Officer

203,700 0.1602%
6/30/26 Free

Chief Technology Officer

213,900 0.1682%
Change 5-day change 1-year change 3-year change Capi.($)
+8.00%-10.60%-65.99%+91.87% 190M
+1.15%-2.81%+55.79%+71.12% 66.37B
+0.87%-1.55%+9.28%+91.21% 58.86B
+0.84%+0.63%+26.19%+86.95% 55.22B
+0.48%-2.53%+9.73%+121.14% 47.21B
-2.69%-6.38%+19.19%+25.79% 42.45B
-0.70%+4.93%+17.77%+45.03% 36.44B
-2.50%-15.73%+135.31%+662.73% 35.19B
-0.13%-2.08%+81.99%+57.07% 32.66B
-0.83%+1.98%-38.27%+390.98% 26.73B
Average +0.45%-4.57%+25.10%+164.39% 40B
Weighted average by Cap. -0.14%-2.19%+34.94%+147.01%

Financials

2026 *2027 *
Net sales 87.22M 79.18M 73.14M 65.99M 125M 8.15B 129M 881M 349M 4.4B 327M 320M 13.89B 101M 92.07M 85.05M 76.73M 145M 9.48B 150M 1.02B 405M 5.11B 381M 373M 16.16B
Net income -109M -99.32M -91.75M -82.77M -156M -10.22B -162M -1.11B -437M -5.52B -410M -402M -17.43B -123M -112M -103M -93.32M -176M -11.52B -183M -1.25B -493M -6.22B -463M -453M -19.65B
Net Debt - -
Projected Income Statement - Annual - ADC Therapeutics SA
Logo ADC Therapeutics SA
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
Employees
191
Date Price Change Volume
26-11-17 $1.350 +8.00% 1,097,116
26-11-16 $1.250 -6.72% 1,480,602
26-11-13 $1.340 -4.96% 1,075,046
26-11-12 $1.410 -11.88% 1,874,102
26-11-11 $1.600 +5.96% 769,034
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - ADC Therapeutics SA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.350USD
Average target price
3.333USD
Spread / Average Target
+146.91%
  1. Stock Market
  2. Stocks
  3. ADCT Stock